TC-1698: Difference between revisions

(17 intermediate revisions by 16 users not shown)

Line 1:

⚫

~~{{Drugbox~~| verifiedrevid = ~~349891046~~

{{Drugbox

|

| Verifiedfields = changed

⚫

|IUPAC_name = 2-pyridin-3-yl-1-azabicyclo[3.2.2]nonane

⚫

| verifiedrevid = 449589216

| image=TC-1698_structure.png

⚫

| IUPAC_name = 2-pyridin-3-yl-1-azabicyclo[3.2.2]nonane

⚫

| width= ~~240~~

| image = TC-1698.svg

⚫

| CAS_number=

⚫

| width = 160

| ATC_prefix=

⚫

| ATC_suffix=

⚫

| PubChem= 10130417

| tradename =

⚫

| legal_status = Legal

⚫

| routes_of_administration =

⚫

| CAS_number = 700834-58-8

⚫

| ATC_suffix =

⚫

| PubChem = 10130417

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 8305933

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| DrugBank=

| ~~C=13~~ ~~| H~~=18 ~~| N=2~~

| ChEMBL = 2151442

| molecular_weight = 202.295

| C=13 | H=18 | N=2

| smiles = c2ncccc2C1CCC3CCN1CC3

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| bioavailability=

| StdInChI = 1S/C13H18N2/c1-2-12(10-14-7-1)13-4-3-11-5-8-15(13)9-6-11/h1-2,7,10-11,13H,3-6,8-9H2

| metabolism =

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| elimination_half-life=

| StdInChIKey = WIEWCOLOPGXZDJ-UHFFFAOYSA-N

| excretion =

| pregnancy_category =

⚫

| legal_status = Legal

⚫

| routes_of_administration=

}}

'''TC-1698''' is a drug developed by [[Targacept]] which acts as a [[partial agonist]] for the [[Alpha-7 nicotinic receptor|α7]] subtype of neural [[nicotinic acetylcholine receptor]]s.<ref>{{~~Cite~~ ~~pmid~~|17295372}}</ref> It has [[neuroprotective]] effects in animal studies,<ref>{{~~Cite~~ ~~pmid~~|14722323}}</ref> and has been used as a [[lead compound]] to find further potent derivatives.<ref>{{~~Cite~~ ~~pmid~~|18363376}}</ref>

'''TC-1698''' is a drug developed by [[Targacept]] which acts as a [[partial agonist]] for the [[Alpha-7 nicotinic receptor|α7]] subtype of neural [[nicotinic acetylcholine receptor]]s.<ref>{{cite journal | vauthors = Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F | title = Central nicotinic receptors: structure, function, ligands, and therapeutic potential | journal = ChemMedChem | volume = 2 | issue = 6 | pages = 746–67 | date = June 2007 | pmid = 17295372 | doi = 10.1002/cmdc.200600207 | s2cid = 34763474 }}</ref> It has [[neuroprotective]] effects in animal studies,<ref>{{cite journal | vauthors = Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M | title = The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 309 | issue = 1 | pages = 16–27 | date = April 2004 | pmid = 14722323 | doi = 10.1124/jpet.103.061655 | s2cid = 7730290 | citeseerx = 10.1.1.420.2457 }}</ref> and has been used as a [[lead compound]] to find further potent derivatives.<ref>{{cite journal | vauthors = Bhatti BS, Strachan JP, Breining SR, Miller CH, Tahiri P, Crooks PA, Deo N, Day CS, Caldwell WS | display-authors = 6 | title = Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands | journal = The Journal of Organic Chemistry | volume = 73 | issue = 9 | pages = 3497–507 | date = May 2008 | pmid = 18363376 | doi = 10.1021/jo800028q }}</ref>

==See also==

* [[Anabasine]]

== References ==

[[Category:Nicotinic agonists]]

[[Category:Stimulants]]

[[Category:~~Pyridines~~]]

[[Category:3-Pyridyl compounds]]